Skip to Main Content

Author Details

Mathew J Garnett
Wellcome Sanger Institute
1998
94
43
PMIDPaper TitleJournal TitlePublished Year
36669486Base editing screens map mutations affecting interferon-γ signaling in cancer.Cancer Cell2023
37020037RAF1 contributes to cell proliferation and STAT3 activation in colorectal cancer independently of microsatellite and KRAS status.Oncogene2023
37380628A landscape of response to drug combinations in non-small cell lung cancer.Nat Commun2023
35197630Effective drug combinations in breast, colon and pancreatic cancer cells.Nature2022
35642948Can Drug Repurposing Accelerate Precision Oncology?Cancer Discov2022
35368031A suspension technique for efficient large-scale cancer organoid culturing and perturbation screens.Sci Rep2022
36241868AKT-mTORC1 reactivation is the dominant resistance driver for PI3Kβ/AKT inhibitors in PTEN-null breast cancer and can be overcome by combining with Mcl-1 inhibitors.Oncogene2022
33068406Project Score database: a resource for investigating cancer cell dependencies and prioritizing therapeutic targets.Nucleic Acids Res2021
33637726Combinatorial CRISPR screen identifies fitness effects of gene paralogues.Nat Commun2021
33692175Use of preclinical models for malignant pleural mesothelioma.Thorax2021
33500573Cancer research needs a better map.Nature2021
34789150CoRe: a robustly benchmarked R package for identifying core-fitness genes in genome-wide pooled CRISPR-Cas9 screens.BMC Genomics2021
34576298Inferred Ancestral Origin of Cancer Cell Lines Associates with Differential Drug Response.Int J Mol Sci2021
34593524MTH1 Inhibitor TH1579 Induces Oxidative DNA Damage and Mitotic Arrest in Acute Myeloid Leukemia.Cancer Res2021
33339894SLFN11 informs on standard of care and novel treatments in a wide range of cancer models.Br J Cancer2021
33273059AZD0364 Is a Potent and Selective ERK1/2 Inhibitor That Enhances Antitumor Activity in <i>KRAS</i>-Mutant Tumor Models when Combined with the MEK Inhibitor, Selumetinib.Mol Cancer Ther2021
32487991Stratification and prediction of drug synergy based on target functional similarity.NPJ Syst Biol Appl2020
35121986Genomics-guided pre-clinical development of cancer therapies.Nat Cancer2020
32073727Patient-specific logic models of signaling pathways from screenings on cancer biopsies to prioritize personalized combination therapies.Mol Syst Biol2020
33438807Patient-specific logic models of signaling pathways from screenings on cancer biopsies to prioritize personalized combination therapies.Mol Syst Biol2020
32627965Drug mechanism-of-action discovery through the integration of pharmacological and CRISPR screens.Mol Syst Biol2020
32990596Genome-wide CRISPR screens of oral squamous cell carcinoma reveal fitness genes in the Hippo pathway.Elife2020
32988967AZD4320, A Dual Inhibitor of Bcl-2 and Bcl-x<sub>L</sub>, Induces Tumor Regression in Hematologic Cancer Models without Dose-limiting Thrombocytopenia.Clin Cancer Res2020
32437684CELLector: Genomics-Guided Selection of Cancer In Vitro Models.Cell Syst2020
27628132Drug Sensitivity Assays of Human Cancer Organoid Cultures.Methods Mol Biol2019
31862961Agreement between two large pan-cancer CRISPR-Cas9 gene dependency data sets.Nat Commun2019
31733513Quantitative Proteome Landscape of the NCI-60 Cancer Cell Lines.iScience2019
30260411Cell Model Passports-a hub for clinical, genetic and functional datasets of preclinical cancer models.Nucleic Acids Res2019
30224339NOTCH1 Represses MCL-1 Levels in GSI-resistant T-ALL, Making them Susceptible to ABT-263.Clin Cancer Res2019
30006863Erratum to: Drug Sensitivity Assays of Human Cancer Organoid Cultures.Methods Mol Biol2019
31209238Community assessment to advance computational prediction of cancer drug combinations in a pharmacogenomic screen.Nat Commun2019
31375513Patient-Derived Xenografts and Matched Cell Lines Identify Pharmacogenomic Vulnerabilities in Colorectal Cancer.Clin Cancer Res2019
31127149Imipridone ONC212 activates orphan G protein-coupled receptor GPR132 and integrated stress response in acute myeloid leukemia.Leukemia2019
31097696Functional linkage of gene fusions to cancer cell fitness assessed by pharmacological and CRISPR-Cas9 screening.Nat Commun2019
30971826Prioritization of cancer therapeutic targets using CRISPR-Cas9 screens.Nature2019
30849372Characterizing Mutational Signatures in Human Cancer Cell Lines Reveals Episodic APOBEC Mutagenesis.Cell2019
30722791Structural rearrangements generate cell-specific, gene-independent CRISPR-Cas9 loss of fitness effects.Genome Biol2019
30674557JACKS: joint analysis of CRISPR/Cas9 knockout screens.Genome Res2019
29186349GDSCTools for mining pharmacogenomic interactions in cancer.Bioinformatics2018
30103702Unsupervised correction of gene-independent cell responses to CRISPR-Cas9 targeting.BMC Genomics2018
29853607Itraconazole targets cell cycle heterogeneity in colorectal cancer.J Exp Med2018
30061675Organoid cultures recapitulate esophageal adenocarcinoma heterogeneity providing a model for clonality studies and precision therapeutics.Nat Commun2018
30139972The germline genetic component of drug sensitivity in cancer cell lines.Nat Commun2018
30553813CellMinerCDB for Integrative Cross-Database Genomics and Pharmacogenomics Analyses of Cancer Cell Lines.iScience2018
30299440Corrigendum: High-throughput RNAi screen for essential genes and drug synergistic combinations in colorectal cancer.Sci Data2018
29634948The Origins and Vulnerabilities of Two Transmissible Cancers in Tasmanian Devils.Cancer Cell2018
29382705Discovery of Potent and Selective MRCK Inhibitors with Therapeutic Effect on Skin Cancer.Cancer Res2018
29157092Single agent and synergistic combinatorial efficacy of first-in-class small molecule imipridone ONC201 in hematological malignancies.Cell Cycle2018
29229604Transcription Factor Activities Enhance Markers of Drug Sensitivity in Cancer.Cancer Res2018
29345617Loss of functional BAP1 augments sensitivity to TRAIL in cancer cells.Elife2018
  • 1 - 50 of 94

Recommended Authors

Graeme Benstead-Hume
The Institute of Cancer Research
Career Start Year 2015
Number of shared co-authors 0
Raunak Shrestha
University of California San Francisco
Career Start Year 2014
Number of shared co-authors 0
Gray R Anderson
Duke University
Career Start Year 2014
Number of shared co-authors 2
Sahil Seth
The University of Texas MD Anderson Cancer Center
Career Start Year 2014
Number of shared co-authors 26
Andrew Goodspeed
University of Colorado Denver | Anschutz Medical Campus
Career Start Year 2013
Number of shared co-authors 2
Frederick S Vizeacoumar
College of Medicine, University of Saskatchewan
Career Start Year 2010
Number of shared co-authors 2
Katherine R Singleton
Duke University
Career Start Year 2009
Number of shared co-authors 4
Sander R van Hooff
Princess Maxima Center for Pediatric Oncology
Career Start Year 2008
Number of shared co-authors 5
Siyuan Zheng
Greehey Children's Cancer Research Institute
Career Start Year 2007
Number of shared co-authors 13
Lawrence N Kwong
The University of Texas MD Anderson Cancer Center
Career Start Year 2007
Number of shared co-authors 10
Barry S Taylor
Memorial Sloan Kettering Cancer Center
Career Start Year 2006
Number of shared co-authors 12
John Paul Shen
The University of Texas MD Anderson Cancer Center
Career Start Year 2006
Number of shared co-authors 4
Kris C Wood
Duke University
Career Start Year 2005
Number of shared co-authors 10
Christopher A Bristow
The University of Texas MD Anderson Cancer Center
Career Start Year 2005
Number of shared co-authors 12
Nikolaus Schultz
Memorial Sloan Kettering Cancer Center
Career Start Year 2003
Number of shared co-authors 24
Elena Ivanova
Dana-Farber Cancer Institute
Career Start Year 2003
Number of shared co-authors 11
Peter Horak
German Cancer Research Center (DKFZ) and National Center for Tumor Diseases (NCT)
Career Start Year 2003
Number of shared co-authors 2
Debyani Chakravarty
Memorial Sloan Kettering Cancer Center
Career Start Year 2002
Number of shared co-authors 9
Trever G Bivona
University of California san francisco
Career Start Year 2002
Number of shared co-authors 11
Nikhil Wagle
Dana-Farber Cancer Institute
Career Start Year 2000
Number of shared co-authors 11
Kevin R Brown
College Street, University of Toronto
Career Start Year 2000
Number of shared co-authors 2
Kenna R Mills Shaw
The University of Texas MD Anderson Cancer Center
Career Start Year 1999
Number of shared co-authors 9
Tobias Sj??blom
Uppsala University
Career Start Year 1999
Number of shared co-authors 2
Charles Swanton
Francis Crick Institute
Career Start Year 1997
Number of shared co-authors 28
Barbara A Weir
Janssen Research and Development LLC
Career Start Year 1997
Number of shared co-authors 18
Li Ding
McDonnell Genome Institute, Washington University School of Medicine
Career Start Year 1997
Number of shared co-authors 20
Peter S Hammerman
Novartis Institutes for BioMedical Research
Career Start Year 1996
Number of shared co-authors 15
Krister Wennerberg
University of Copenhagen
Career Start Year 1994
Number of shared co-authors 18
Levi A Garraway
Broad Institute of Harvard and MIT
Career Start Year 1991
Number of shared co-authors 25
E Alejandro Sweet-Cordero
University of California San Francisco
Career Start Year 1989
Number of shared co-authors 10

Collaborators

Ultan McDermott
Wellcome Sanger Institute
Co-authored papers 35
Cyril H Benes
Co-authored papers 20
Julio Saez-Rodriguez
Institute of Computational Biomedicine, Heidelberg University
Co-authored papers 20
Patricia Jaaks
Wellcome Sanger Institute
Co-authored papers 10
Lodewyk F A Wessels
University Medical Centre Mannheim, University of Heidelberg
Co-authored papers 9
Michael R Stratton
Wellcome Sanger Institute
Co-authored papers 8
Kosuke Yusa
Wellcome Sanger Institute
Co-authored papers 7
Elizabeth A Coker
Wellcome Sanger Institute
Co-authored papers 6
Euan A Stronach
Imperial College London
Co-authored papers 5
Adam Butler
Wellcome Sanger Institute
Co-authored papers 4
David J Adams
Wellcome Sanger Institute
Co-authored papers 4
Stephen Fawell
Oncology R&D
Co-authored papers 4
Ludmil B Alexandrov
Moores Cancer Center, university of california san diego
Co-authored papers 3
Poul H Sorensen
British Columbia Cancer Research Centre
Co-authored papers 3
Rebecca Shepherd
Murdoch Children's Research Institute, Royal Children's Hospital
Co-authored papers 3
James G R Gilbert
Wellcome Sanger Institute
Co-authored papers 3
Barry R Davies
Oncology R&D
Co-authored papers 3
Phillip A Futreal
The University of Texas MD Anderson Cancer Center
Co-authored papers 3
David C Wedge
Manchester Cancer Research Centre, University of Manchester
Co-authored papers 3
Livio Trusolino
Candiolo Cancer Institute - FPO IRCCS
Co-authored papers 3
Joshua E Allen
Co-authored papers 3
Theo A Knijnenburg
Allen Institute for Cell Science
Co-authored papers 3
Elizabeth Anderson
Wellcome Sanger Institute
Co-authored papers 3
Andrea Bertotti
Candiolo Cancer Institute - FPO IRCCS
Co-authored papers 3
Stephen P Jackson
Mission Therapeutics Ltd. Glenn Berge Building
Co-authored papers 2
Vinodh N Rajapakse
Co-authored papers 2
Carlos Caldas
Cancer Research UK Cambridge Institute, University of Cambridge
Co-authored papers 2
Oliver Stegle
Wellcome Sanger Institute
Co-authored papers 2
Emile E Voest
The Netherlands Cancer Institute
Co-authored papers 2
José Baselga
Co-authored papers 2
Release 1.2